ACDM AI Conference Report

At the two-day ACDM AI symposium 2025 in Frankfurt, QFINITY – through COO Marcus Schwabedissen, a standing steering-committee member – again contributed expertise on the validation, compliance, and ethics of AI-enabled systems and led the corresponding track.

In his opening remarks, Ashley Howard reflects on the first ACDM AI Symposium held in London. The photo features, among others, Oliver Herrmann (CEO, QFINITY) taking part in the major panel discussion of 2022.

Following the success of the ACDM AI Conferences over the past three years and the rapid pace of development in Artificial Intelligence, ACDM once again hosted a two-day AI Conference in June 2025.

Responsible AI in clinical trials means being integrated into data-critical processes in a way that is regulatory-robust and ethically sound.

The AI Conference offered a diverse program including innovative training sessions, hands-on case studies, engaging presentations, expert panels, and numerous networking opportunities. The aim was to further the responsible use of AI technologies in clinical trials. Representatives from pharmaceutical companies, CROs, and technology providers gathered in Frankfurt to discuss current developments and future directions in Artificial Intelligence.

QFINITY once again supported the event through Marcus Schwabedissen, COO and a permanent Steering Committee member since 2022, who helped plan, prepare, and run it. He chaired the track on validation, compliance, and ethics in AI.

Given the positive feedback, ACDM looks forward to more successful AI Symposia in the future.

For more information about ACDM events, please click here.